DRUG PROFILE OF SOFOSBUVIR - A NUCLEOTIDE ANALOG INHIBITOR OF THE HEPATITIS C VIRUS POLYMERASE
V.R.Ghayathri *, C.Vinodhini, S.Gayatri, K.Chitra
ABSTRACT
Sofosbuvir is the drug of choice for hepatitis C virus (HCV) infection,
with a high cure rate. Sofosbuvir is a component of the first all-oral,
interferon-free regimen approved by FDA for treatment of chronic
hepatitis C. It inhibits the RNA polymerase that the hepatitis C virus
uses to replicate its RNA. This review describes the drug profile of
sofosbuvir that may recommend major treatment advantages over live
benefits.
Keywords: Sofosbuvir, Hepatitis C , GS 331007 , FDA
[Download Article]
[Download Certifiate]